KLRK1 and hematopoietic and lymphoid cell neoplasm: While NKG2D-CAR T cells have shown impressive benefits in hematological cancer patients, challenges remain in the context of solid tumors, including poor persistence of T cells and immunosuppression [2, 6, 31].